Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Large language models extract diverse manifestations of chronic GVHD from unstructured clinical documentation

John Lazar, Lloyd Damon, Neil Dunavin, Timothy Ferng, Karin Gaensler, Krishna Komanduri, Jerry Lee, Aaron Logan, Rebecca Olin, Tamer Othman, Peter Sayre, Travis Zack, Catherine Smith

Blood (2025) 146 (Supplement 1): 7763.

https://doi.org/10.1182/blood-2025-7763

Published: 2025

Journal Articles

Treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia using hypercvad with ponatinib is associated with excellent survival with selective use of blinatumomab and allogeneic hematopoietic cell transplantation

Jiyong Ahn, Mimi Lo, Lily Yan, Lloyd Damon, Neil Dunavin, Timothy Ferng, Karin Gaensler, Jerry Lee, Tamer Othman, Peter Sayre, Catherine Smith, Rebecca Olin, Aaron Logan

Blood (2025) 146 (Supplement 1): 3346.

https://doi.org/10.1182/blood-2025-3346

Published: 2025

Journal Articles

Post-transplant FLT3 inhibitor maintenance is associated with improved survival in FLT3-ITD positive acute myelogenous leukemia irrespective of pre-transplant MRD status

Tamer Othman, Nicole Lei, Lloyd Damon, Neil Dunavin, Timothy Ferng, Karin Gaensler, Jerry Lee, Rebecca Olin, Peter Sayre, Catherine Smith, Aaron Logan

Blood (2025) 146 (Supplement 1): 6057.

https://doi.org/10.1182/blood-2025-6057

Published: 2025

Journal Articles

Front-line treatment of Philadelphia negative B-cell acute lymphoblastic leukemia with hypercvad with blinatumomab

Aaron Logan, Mimi Lo, Lloyd Damon, Neil Dunavin, Timothy Ferng, Karin Gaensler, Jerry Lee, Tamer Othman, Peter Sayre, Catherine Smith, Rebecca Olin

Blood (2025) 146 (Supplement 1): 6861.

https://doi.org/10.1182/blood-2025-6861

Published: 2025

Journal Articles

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Blood (2024) 144 (Supplement 1): 212.

https://doi.org/10.1182/blood-2024-207106

Published: 2024

Journal Articles

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Blood (2024) 144 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2024-206538

Published: 2024

Journal Articles

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Blood (2023) 142 (Supplement 1): 57.

https://doi.org/10.1182/blood-2023-172422

Published: 2023

Journal Articles

Improved Gvhd and Relapse Free Survival Outcomes in Older Acute Leukemia Patients Receiving Young Haploidentical Donor Vs Older Matched Sibling Donor Reduced Intensity Conditioning Hematopoietic Cell Transplants

Andrew H. Tam, Aaron C. Logan, Angela J. Choi, Richard Fong, Lloyd E. Damon, Rebecca L. Olin, Neil Dunavin, Peter H. Sayre, Karin L. Gaensler, Catherine Smith, Lily Yan

Blood (2022) 140 (Supplement 1): 4895–4896.

https://doi.org/10.1182/blood-2022-164862

Published: 2022

Journal Articles

LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing

Haitham Abdelhakim, MD, Luis M. Cortez, BS, Meizhang Li, PhD, Mitchell Braun, BS, Barry S. Skikne, MD, Tara L. Lin, MD, Neil Dunavin, MD, Andrew K Godwin, PhD

Blood (2019) 134 (Supplement_1): 3605.

https://doi.org/10.1182/blood-2019-129455

Published: 2019

Journal Articles

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Barry S. Skikne, MD, Anurag K. Singh, MD, Sunil Abhyankar, MD, Tara L. Lin, MD, Leyla Shune, MD, Neil Dunavin, MD, Ajoy L. Dias, MD, Brian McClune, DO, Abdulraheem Yacoub, MD, Clint Divine, Haitham Abdelhakim, MD, Siddhartha Ganguly, MD, Jennifer Hanses, Carol E Webb, BA, Joseph P. McGuirk, DO

Blood (2019) 134 (Supplement_1): 5743.

https://doi.org/10.1182/blood-2019-130828

Published: 2019

Journal Articles

LAG3 Promotes Acute Myeloid Leukemia-Induced Immune Suppression

Haitham Abdelhakim, MD, Neil Dunavin, MD, Meizhang Li, PhD, Mitchell Braun, BS, Ahmed Elkhanany, MD, Tara L Lin, MD, Andrew K Godwin, PhD

Blood (2018) 132 (Supplement 1): 2414.

https://doi.org/10.1182/blood-2018-99-117784

Published: 2018

Journal Articles

CRISPR/Cas9-Mediated Disruption of PD-L1 Reduces the T Cell Suppressive Effect of Wharton's Jelly Mesenchymal Stromal Cells and Their Extracellular Vesicles

Neil Dunavin, MD, Meizhang Li, PhD, Safinur Atay, PhD, Jim Mitchell, Rupal Soder, PhD, Sunil Abhyankar, MD, Joseph P. McGuirk, DO, Andrew K Godwin, PhD, Buddhadeb Dawn, MD

Blood (2018) 132 (Supplement 1): 5095.

https://doi.org/10.1182/blood-2018-99-116921

Published: 2018

Journal Articles

Health Care Reimbursement and Service Utilization Among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings

Neil Dunavin, MD, Lih-Wen Mau, PhD MPH, Christa Lea Meyer, MS, Clint Divine, Al-Ola Abdallah, MD, Susan Leppke, MPH, Anita D'Souza, MBBS, Ellen Denzen, MS, Wael Saber, MD MS, Linda J. Burns, MD, Siddhartha Ganguly, MD

Blood (2018) 132 (Supplement 1): 832.

https://doi.org/10.1182/blood-2018-99-118423

Published: 2018

Journal Articles

Daratumumab, Pomalidomide, and Dexamethasone (DPd) As Salvage Treatment for Relapsed/Refractory Myeloma Eligible for High-Dose Chemotherapy/Autologous Stem Cell Transplantation

Al-Ola Abdallah, MD, Neil Dunavin, MD, Brian McClune, DO, Leyla Shune, MD, Ajoy L. Dias, MD, Zahra Mahmoudjafari, PhD, Erica Hochard, PhD, Joseph P. McGuirk, DO, Siddhartha Ganguly, MD

Blood (2018) 132 (Supplement 1): 5760.

https://doi.org/10.1182/blood-2018-99-117654

Published: 2018

Journal Articles

Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience

Al-Ola Abdallah, MD, Neil Dunavin, MD, Brian McClune, DO, Leyla Shune, MD, Ajoy L. Dias, MD, Zahra Mahmoudjafari, PhD, Erica Hochard, PhD, Joseph P. McGuirk, DO, Siddhartha Ganguly, MD

Blood (2018) 132 (Supplement 1): 5642.

https://doi.org/10.1182/blood-2018-99-117497

Published: 2018

Journal Articles

Outcomes of Vdpace with Immunomodulator Treatment in Initial and Relapsed/Refractory Multiple Myeloma in a Single Center

Al-Ola Abdallah, MD, Joseph P. McGuirk, DO, Leyla Shune, MD, Erica Hochard, PhD, Neil Dunavin, MD, Zahra Mahmoudjafari, PhD, Siddhartha Ganguly, MD

Blood (2017) 130 (Supplement 1): 5422.

https://doi.org/10.1182/blood.V130.Suppl_1.5422.5422

Published: 2017

Journal Articles

Incidence and Risk Factors of Epstein-Barr Virus Viremia in Patients Undergoing Haploidential Transplantation with Post Translant Cyclophosphamide

Ghulam Rehman Mohyuddin, MD, Shaun DeJarnette, Leyla Shune, MD, Tara L. Lin, MD, Neil Dunavin, MD, Ajoy L. Dias, MD, Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Joseph P. McGuirk, DO, Anurag K. Singh, MD

Blood (2017) 130 (Supplement 1): 5557.

https://doi.org/10.1182/blood.V130.Suppl_1.5557.5557

Published: 2017

Journal Articles

Successful Management of Treatment-Emergent Chronic Graft-Versus-Host Disease of the Liver Following Nivolumab for Relapsed Hodgkin's Lymphoma after Allogeneic Stem Cell Transplant

Mitchell Braun, BS, Neil Dunavin, MD, Maxwell Pike, MD, Ajoy L. Dias, MD, Tara L. Lin, MD, Leyla Shune, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Anurag K. Singh, MD, Sunil Abhyankar, MD

Blood (2017) 130 (Supplement 1): 5492.

https://doi.org/10.1182/blood.V130.Suppl_1.5492.5492

Published: 2017

Journal Articles

Chemotherapy-Refractory Acute Myeloid Leukemia and Outcomes after Allogeneic Stem Cell Transplantation—a Single Center Analysis

Kapil Kohli, MD, Ajoy L. Dias, MD, Neil Dunavin, MD, Leyla Shune, MD, Tara L. Lin, MD, Sunil Abhyankar, MD, Anurag K. Singh, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Barry S. Skikne, MD

Blood (2017) 130 (Supplement 1): 5541.

https://doi.org/10.1182/blood.V130.Suppl_1.5541.5541

Published: 2017

Journal Articles

Daratumumab Combined with Pomalidomide and Dexamethasone (DPd) for Patients with Relapsed/Refractory Multiple Myeloma in a Single Institution

Al-Ola Abdallah, MD, Joseph P. McGuirk, DO, Leyla Shune, MD, Neil Dunavin, MD, Zahra Mahmoudjafari, PhD, Erica Hochard, PhD, Siddhartha Ganguly, MD

Blood (2017) 130 (Supplement 1): 1856.

https://doi.org/10.1182/blood.V130.Suppl_1.1856.1856

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Large language models extract diverse manifestations of chronic GVHD from unstructured clinical documentation

Treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia using hypercvad with ponatinib is associated with excellent survival with selective use of blinatumomab and allogeneic hematopoietic cell transplantation

Post-transplant FLT3 inhibitor maintenance is associated with improved survival in FLT3-ITD positive acute myelogenous leukemia irrespective of pre-transplant MRD status

Front-line treatment of Philadelphia negative B-cell acute lymphoblastic leukemia with hypercvad with blinatumomab

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Improved Gvhd and Relapse Free Survival Outcomes in Older Acute Leukemia Patients Receiving Young Haploidentical Donor Vs Older Matched Sibling Donor Reduced Intensity Conditioning Hematopoietic Cell Transplants

LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

LAG3 Promotes Acute Myeloid Leukemia-Induced Immune Suppression

CRISPR/Cas9-Mediated Disruption of PD-L1 Reduces the T Cell Suppressive Effect of Wharton's Jelly Mesenchymal Stromal Cells and Their Extracellular Vesicles

Health Care Reimbursement and Service Utilization Among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings

Daratumumab, Pomalidomide, and Dexamethasone (DPd) As Salvage Treatment for Relapsed/Refractory Myeloma Eligible for High-Dose Chemotherapy/Autologous Stem Cell Transplantation

Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience

Outcomes of Vdpace with Immunomodulator Treatment in Initial and Relapsed/Refractory Multiple Myeloma in a Single Center

Incidence and Risk Factors of Epstein-Barr Virus Viremia in Patients Undergoing Haploidential Transplantation with Post Translant Cyclophosphamide

Successful Management of Treatment-Emergent Chronic Graft-Versus-Host Disease of the Liver Following Nivolumab for Relapsed Hodgkin's Lymphoma after Allogeneic Stem Cell Transplant

Chemotherapy-Refractory Acute Myeloid Leukemia and Outcomes after Allogeneic Stem Cell Transplantation—a Single Center Analysis

Daratumumab Combined with Pomalidomide and Dexamethasone (DPd) for Patients with Relapsed/Refractory Multiple Myeloma in a Single Institution

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only